Valeant Pharmaceuticals Intl (NYSE: VRX) Investor Class Action Lawsuit

Our law firm is investigating potential claims on behalf of shareholders of Valeant Pharmaceuticals Intl (NYSE: VRX) over possible violations of US securities laws.

Did you lose more than $100,000 in VRX Stock? Did you purchase before March 2016? If so, you may be entitled to compensation,
Call 1-800-934-2921 or complete the form on this page for a free consultation.

Our law firm is investigating potential claims on behalf of shareholders of Valeant Pharmaceuticals Intl (NYSE: VRX) over possible violations of US securities laws due to possible breaches of fiduciary duty by officers of the company. If you have purchased more than $100,000 in shares of Valeant Pharmaceuticals Intl (NYSE: VRX) before March 16th, 2016, contact our law firm right now to protect your rights.

Due to allegedly fraudulent practices by management, VRX investors have recently been saddled with significant losses. Recent reports have claimed that Valeant Pharmaceuticals International Inc. refilled patients’ prescriptions without their permission and steered them to more expensive drugs in order to boost sales and profits, leading to investors to potentially overvalue the company.

In a recently filed lawsuit, a large pension fund that invested in VRX claimed that Valeant formed a secret network of pharmacies to artificially inflate the sale of its drugs using a number of fraudulent and improper practices, including physically changing doctors’ orders to require prescriptions be filled with Valeant products instead of available cheaper generics and automatically refilling prescriptions for Valeant drugs even though the patients didn’t need refills.

Own shares of VRX? Contact us to protect your rights. – Valeant Pharmaceuticals Intl  VRX Investor Lawsuit

If you have purchased shares of Valeant Pharmaceuticals Intl (NYSE: VRX), complete the form on this page or call 1-800-934-2921 right now to protect your rights.


VRX stock drop causes huge losses for investors.

Valeant Pharmaceuticals took a big hit as investors cut the value of the company’s stock in

VRX Shareholder Losses Lawsuit

VRX Shareholder Losses Lawsuit

half. In a single day, the stock plunged more than 51 percent due to fears of the company defaulting on its debt. The company also reported weaker than expected earnings and analysts cut its forecast for 2016. When the dust settled, Valeant stock lost nearly 61 percent of its value in a week. The earnings announcement cost the company nearly $13 billion in market capitalization.

Analysts expected the company to report a net profit of nearly $463 million. When the company released its earnings, they actually reported a net loss of $336 million. The huge contrast in earnings caused the stock to drop within minutes of the company’s announcement. Valeant reported that the net loss was in large part due to the company’s acquisition and restructuring costs. In another twist, the company reported it will delay its annual report for 2015 with the Securities and Exchange Commission.

The company also launched an internal investigation into its relationship with the online pharmacy company Philidor. According to Valeant, the company documented nearly $55 million in sales to Philidor at the wrong time. Due to the misstep, Valeant now has to restate earnings for all of 2014 and 2015. If Valeant cannot report 2015 earnings to the SEC in time, the company runs the risk of defaulting on its long-term debt. Reports indicate that Valeant’s long-term debt stands at $30 billion.

During the company’s earnings announcement, CEO Michael Pearson did not give any guidance on how he plans to pay down the debt. Pearson plans to step down as CEO once the company finds his replacement. The company did announce that Bill Ackman, who runs the hedge fund Pershing Square Capital Management, will join Valeant’s board of directors.

Did you lose more than $100,000 in VRX Stock? Did you purchase before March 2016? Contact us to protect your rights. – Valeant Pharmaceuticals Intl VRX Investor Class Action Lawsuit

If you have purchased more than $100,000 in shares of Valeant Pharmaceuticals Intl (NYSE: VRX) before March 16th, 2016, contact our law firm right now to protect your rights. Complete the form on this page or call 1-800-934-2921 right now to protect your rights.

Written by

Comments are closed.